MHRA denies Oral Paclitaxel for metastatic breast cancer based solely on chemistry, manufacturing and control (CMC) issuesAthenex plans to request a review of the MHRA decision by an independent panel The MHRA application was supplemented with safety data from the iSPY 2 study and no major clinical ...

Thinking about buying stock in Athenex, Camber Energy, Mullen Automotive, Iamgold, or United States Steel? Thinking about buying stock in Athenex, Camber Energy, Mullen Automotive, Iamgold, or United States Steel? PR Newswire NEW YORK, Dec. 20, 2022 NEW YORK, Dec. 20, 2022 /PRNewswire...

Oral Paclitaxel combination regimen has graduated in this Phase 2 trial in the triple negative breast cancer subgroupBUFFALO, N.Y., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of ...

Full-year 2022 product sales guidance maintained at 20-25% growth year-over-yearBUFFALO, N.Y., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of ...

Shareholders voted in favor of all three proposals submitted before the Special Stockholder Meeting BUFFALO, N.Y., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for...